LB2307. Safety and Efficacy of Letermovir (LET) versus Valganciclovir (VGCV) for Prevention of Cytomegalovirus (CMV) Disease in Kidney Transplant Recipients (KTRs): A Phase 3 Randomized Study

BACKGROUND: VGCV is approved for prophylaxis in adult KTRs at high risk for CMV disease (donor CMV-seropositive/recipient CMV-seronegative [D+/R-]); however, its use is limited by myelosuppression. LET is non-myelotoxic, does not require dose modification in renal impairment, and is approved for pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Limaye, Ajit P, Budde, Klemens, Humar, Atul, Garcia-Diaz, Julia, Carroll, Robert P, Murata, Yoshihiko, Teal, Valerie L, Gilbert, Christopher L, Haber, Barbara A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752623/
http://dx.doi.org/10.1093/ofid/ofac492.1897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752623/
http://dx.doi.org/10.1093/ofid/ofac492.1897

Ejemplares similares